✨ Medicines Consents
8 NOVEMBER 2007 NEW ZEALAND GAZETTE, No. 120 3157
Product: Redken 5th Avenue NYC Scalp Relief Anti-Dandruff Shampoo for Dry, Flaking Scalp & Hair
Active Ingredient: Pyrithione zinc 0.9898%w/v
Dosage Form: Shampoo
New Zealand Sponsor: L’Oreal New Zealand Limited
Manufacturer: L’Oreal Products USA Inc., Florence, United States of America
Product: Redken 5th Avenue NYC Scalp Relief Dandruff Control Leave-In Treatment for Dry Flaking Scalp & Hair
Active Ingredient: Pyrithione zinc 0.1008%w/v
Dosage Form: Scalp lotion
New Zealand Sponsor: L’Oreal New Zealand Limited
Manufacturer: Medicia Corporation, Dayton, United States of America
Dated this 1st day of November 2007.
JOHN HAZELDINE, Acting Deputy Director-General, Sector Accountability and Funding Directorate (pursuant to delegation given by the Minister of Health on 6 July 2001).
go7622
Provisional Consent to the Distribution of New Medicines
Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
Product: Rapamune
Active Ingredient: Sirolimus 1mg/mL
Dosage Form: Oral solution
New Zealand Sponsor: Wyeth (NZ) Limited
Manufacturer: Wyeth Pharmaceuticals Inc, New York, United States of America
Note: This consent is valid for two years from the date of publication of this notice.
Product: Synercid
Active Ingredients: Dalfopristin 350mg
Quinupristin 150mg
Dosage Form: Powder for infusion
New Zealand Sponsor: Pharmacy Retailing (NZ) Limited t/a Healthcare Logistics
Manufacturer: DSM Pharmaceuticals Inc, Greenville, North Carolina, United States of America
Note: This consent is valid for two years from the date of publication of this notice.
Dated this 1st day of November 2007.
JOHN HAZELDINE, Acting Deputy Director-General, Sector Accountability and Funding Directorate (pursuant to delegation given by the Minister of Health on 6 July 2001).
go7623
Renewal of Provisional Consent to the Distribution of New Medicines
Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
Product: Chlorquin
Active Ingredient: Chloroquine phosphate 250mg equivalent to 155mg chloroquine base
Dosage Form: Tablet
New Zealand Sponsor: Pharmacy Retailing (NZ) Limited t/a Healthcare Logistics
Manufacturer: Sigma Pharmaceuticals Pty Limited, Baulkham Hills, New South Wales, Australia
Note: This consent is valid for two years from 13 October 2007.
Product: Colgout
Active Ingredient: Colchicine 0.5mg
Dosage Form: Tablet
New Zealand Sponsor: Pharmacy Retailing (NZ) Limited t/a Healthcare Logistics
Manufacturer: Strides Arcolab Limited, Anekal Taluk, Bangalore, India
Note: This consent is valid for two years from 29 September 2007.
Product: Normison
Active Ingredient: Temazepam 10mg
Dosage Form: Tablet
New Zealand Sponsor: Pharmacy Retailing (NZ) Limited t/a Healthcare Logistics
Manufacturer: Sigma Pharmaceuticals Pty Limited, Dandenong, Victoria, Australia
Note: This consent is valid for two years from 24 November 2007.
Next Page →
Online Sources for this page:
VUW Te Waharoa —
NZ Gazette 2007, No 120
Gazette.govt.nz —
NZ Gazette 2007, No 120
✨ LLM interpretation of page content
🏥
Consent to Distribution of New Related Products under Medicines Act
(continued from previous page)
🏥 Health & Social Welfare1 November 2007
Medicines Act, New Products, Redken, L'Oreal
- JOHN HAZELDINE, Acting Deputy Director-General, Sector Accountability and Funding Directorate
🏥 Provisional Consent to the Distribution of New Medicines
🏥 Health & Social Welfare1 November 2007
Medicines Act, Provisional Consent, Rapamune, Synercid
- JOHN HAZELDINE, Acting Deputy Director-General, Sector Accountability and Funding Directorate
🏥 Renewal of Provisional Consent to the Distribution of New Medicines
🏥 Health & Social Welfare1 November 2007
Medicines Act, Renewal of Provisional Consent, Chlorquin, Colgout, Normison
- JOHN HAZELDINE, Acting Deputy Director-General, Sector Accountability and Funding Directorate